Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported strong full-year FY26 results with consolidated revenue from operations of ₹64,306.50 million, up 14.5% YoY from ₹56,165.04 million. Profit after tax (PAT) more than doubled to ₹14,583.03 million from ₹7,539.13 million, representing a 93.5% PAT growth driven by higher other income and operational efficiency. For Q4 standalone, revenue was ₹17,427.90 million with PAT of ₹4,675.89 million. The auditors (Deloitte Haskins & Sells) issued an unmodified opinion on the annual audited results. An exceptional item of ₹243.46 million was recorded due to additional gratuity and leave liability provisions under new Indian Labour Codes. The Board recommended a final dividend of ₹20 per equity share (2000% on face value of ₹1).
The 93.5% PAT growth and clean audit signal strong operational performance, which should be positive for the stock. The ₹20 dividend reinforces shareholder returns. However, non-controlling interests showed a loss of ₹553.87 million for the year, indicating subsidiary-level challenges.